A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 909,734 shares of PTGX stock, worth $40.5 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
909,734
Previous 909,734 -0.0%
Holding current value
$40.5 Million
Previous $31.5 Million -0.0%
% of portfolio
0.09%
Previous 0.09%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$24.66 - $34.8 $7.16 Million - $10.1 Million
-290,168 Reduced 24.18%
909,734 $31.5 Million
Q1 2024

May 15, 2024

SELL
$21.79 - $32.15 $30.8 Million - $45.4 Million
-1,413,551 Reduced 54.09%
1,199,902 $34.7 Million
Q4 2023

Feb 14, 2024

BUY
$14.05 - $23.44 $21.1 Million - $35.3 Million
1,505,313 Added 135.84%
2,613,453 $59.9 Million
Q3 2023

Nov 14, 2023

BUY
$16.68 - $23.66 $18.5 Million - $26.2 Million
1,108,140 New
1,108,140 $18.5 Million
Q1 2023

May 15, 2023

SELL
$10.78 - $25.38 $3.41 Million - $8.03 Million
-316,500 Closed
0 $0
Q4 2022

Feb 14, 2023

SELL
$7.36 - $11.17 $16.4 Million - $24.8 Million
-2,221,493 Reduced 87.53%
316,500 $3.45 Million
Q3 2022

Nov 14, 2022

SELL
$7.86 - $11.71 $11.9 Million - $17.8 Million
-1,518,207 Reduced 37.43%
2,537,993 $21.4 Million
Q2 2022

Aug 15, 2022

BUY
$7.06 - $25.52 $8.06 Million - $29.1 Million
1,141,100 Added 39.14%
4,056,200 $32.1 Million
Q1 2022

May 16, 2022

BUY
$23.34 - $36.08 $11.6 Million - $17.9 Million
495,337 Added 20.47%
2,915,100 $69 Million
Q4 2021

Feb 14, 2022

SELL
$17.63 - $37.1 $34.7 Million - $73 Million
-1,967,537 Reduced 44.85%
2,419,763 $82.8 Million
Q3 2021

Nov 15, 2021

BUY
$12.95 - $49.69 $41.9 Million - $161 Million
3,232,100 Added 279.79%
4,387,300 $77.7 Million
Q2 2021

Aug 16, 2021

BUY
$25.57 - $44.88 $5.44 Million - $9.55 Million
212,900 Added 22.59%
1,155,200 $51.8 Million
Q1 2021

May 17, 2021

BUY
$19.02 - $31.15 $7.46 Million - $12.2 Million
392,300 Added 71.33%
942,300 $24.4 Million
Q4 2020

Feb 16, 2021

BUY
$18.49 - $25.13 $10.2 Million - $13.8 Million
550,000 New
550,000 $11.1 Million
Q4 2019

Feb 14, 2020

SELL
$4.69 - $13.45 $762,125 - $2.19 Million
-162,500 Closed
0 $0
Q3 2019

Nov 15, 2019

BUY
$9.41 - $16.56 $1.53 Million - $2.69 Million
162,500 New
162,500 $1.95 Million
Q1 2018

May 15, 2018

SELL
$8.46 - $23.08 $1.02 Million - $2.77 Million
-120,000 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$14.47 - $20.8 $1.74 Million - $2.5 Million
120,000
120,000 $2.5 Million

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.19B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.